Application Site Rash in Haleon Us Holdings Llc Drugs

2 drug(s) with this reaction

1,412 total reports

Overview

Application Site Rash has been reported as an adverse reaction across 2 drug(s) manufactured by Haleon Us Holdings Llc in the FDA Adverse Event Reporting System (FAERS) database. A combined total of 1,412 adverse event reports mention application site rash in connection with Haleon Us Holdings Llc products.

This page provides a breakdown of which Haleon Us Holdings Llc drugs are most commonly associated with application site rash, along with report counts and links to detailed safety analyses for each medication. Understanding which drugs from a single manufacturer share a common adverse reaction can help patients and healthcare providers identify potential class-wide safety patterns.

Haleon Us Holdings Llc Drugs Reporting Application Site Rash

The following Haleon Us Holdings Llc drugs have application site rash listed in their FDA adverse event reports, sorted by report count:

Other Reactions Reported for Haleon Us Holdings Llc Drugs

In addition to application site rash, the following adverse reactions have been reported across Haleon Us Holdings Llc's drug portfolio:

DRUG INEFFECTIVEPRODUCT USE IN UNAPPROVED INDICATIONDRUG EFFECTIVE FOR UNAPPROVED INDICATIONHEADACHENAUSEAFATIGUEDIZZINESSPAINMIGRAINEVOMITINGABDOMINAL PAIN UPPERINCORRECT DOSE ADMINISTEREDINSOMNIAOFF LABEL USEDIARRHOEAFEELING ABNORMALABDOMINAL DISCOMFORTMALAISEOVERDOSETHERAPEUTIC RESPONSE UNEXPECTED

Frequently Asked Questions

Which Haleon Us Holdings Llc drugs cause Application Site Rash?

2 drug(s) manufactured by Haleon Us Holdings Llc have application site rash listed in their FDA adverse event reports: NICOTINE, NICOTINE POLACRILEX.

How many Application Site Rash reports are there for Haleon Us Holdings Llc drugs?

There are a combined 1,412 reports of application site rash across 2 Haleon Us Holdings Llc drug(s) in the FDA adverse event database.

Related Pages

All Haleon Us Holdings Llc DrugsAll Drugs Causing Application Site Rash
Disclaimer: This analysis is based on FDA adverse event reports and is for informational purposes only. Reports do not prove causation. Always consult your healthcare provider.